

**BRUSSELS
SOUTH
CHARLEROI
BIOPARK**



**CELL AND GENE
THERAPY
ACCELERATOR**

**FREQUENTLY ASKED
QUESTIONS**

June 2021

CELL AND GENE THERAPY ACCELERATOR FAQs

BRUSSELS
SOUTH
CHARLEROI
BIOPARK



- **Who should apply to the program?**

Academic, industry and independent researchers who haven't yet formed a company are preferred, but early-stage companies are also welcome to apply. Applicants are welcome from across the EU.

- **What are the objectives of the program?**

Selected as European cell and gene therapy headquarters by global CMOs such as Catalent, ThermoFisher Scientific and Exothera, **Brussels South Charleroi BioPark** accounts for 20% of the European cell and gene therapy manufacturing capacity with a vibrant innovation pipeline. The new cell and gene therapy accelerator program brings the expertise of these partners together to help develop the next generation of safer, more effective cell and gene therapies, forming companies around them.

CELL AND GENE THERAPY ACCELERATOR FAQs

BRUSSELS
SOUTH
CHARLEROI
BIOPARK



- Who are the program partners?

PARTNERING ORGANISATIONS

FUNDING



ACADEMIA



CMOS



BIOTECHS



R&D SERVICES



CELL AND GENE THERAPY ACCELERATOR FAQs

BRUSSELS
SOUTH
CHARLEROI
BIOPARK



- **How will the program accelerate the progress of my project/technology?**

Complemented by the input of our expert partners, the bootcamp and mentoring, the proof-of-concept funding will enable researchers to significantly de-risk their projects and increase the chances of success at the next fundraising round.

- **What are the timelines for the program? Where and how will the program take place?**

Launch June 28; Close August 13; Program start 20 September 2021, for 12-18 months. The program will be a mix of virtual and in person (in Charleroi – Brussels South) activities

- **What infrastructure can researchers access?**

There will be access to the fully equipped ULB Open BioLab and state of the art technology platforms including bioimaging, microscopy, digital pathology, biomedical image analysis, flow cytometry, genomics, transcriptomics, proteomics, metabolomics and animal models. A clinical trials network is also in place.

- **Do we have to form a company to take part in the program? Will my University technology transfer office be involved?**

BSCB will help successful applicants create a company, located on the Park, around their project. Applicants' technology transfer offices will be involved.



- **What costs are involved?**

Up to the point at which the three successful companies are awarded the funds for their proof-of-concept work, all advice and coaching from the Advisory Panel members will be free of charge.

Each of the three companies will follow a bespoke mentoring program depending on their individual projects. Shared content such as business workshops, lectures from keynote speakers and master classes will be free of charge.

There will be costs associated with use of the **ULB Open BioLab**, and input from the Advisory Panel eg for writing grant applications, providing management support in order to help companies deliver on milestones. The company must spend at least four two per month in coaching/mentoring sessions with a dedicated expert from the BSCB SEED ACCELERATOR up to a total of €10,000 across the program. These hands-on productive sessions will be designed to ensure the achievement of key milestones to be presented to the Advisory Committee every 4 to 6 months.

CELL AND GENE THERAPY ACCELERATOR FAQs

BRUSSELS
SOUTH
CHARLEROI
BIOPARK



- **What topics will be covered on the program?**

#	1	2	3	4	5	6
Module	Value proposition	Product development	Corporate Development	Business Model	Funding	Communication
A	Target validation	Disease models	Incorporation	Disease area /Product portfolio strategy	Financial planning	Mission
B	Associated pathologies	Early efficacy & toxicity	IP strategy	Outsourcing strategy/In house capacity building	Non-dilutive funding	Key messages
C	Unmet medical needs	Early CMC preparedness	Strategic providers	Deal watching/Licencing & partnerships	Tax incentives	Website
D	Modes of action	Early regulatory preparedness	Early Quality by Design preparedness	SWOT analysis & mitigation plan	VC preparedness	LinkedIn company page
E	Targeted Product Profile	Early clinical preparedness	Key team members	Revenue model	Pitch Deck	News flow
F	Associated markets & positioning	Development plan	SAB & Board of Directors	Business Plan	VC network	Channels

CELL AND GENE THERAPY ACCELERATOR FAQs

BRUSSELS
SOUTH
CHARLEROI
BIOPARK



- **What reach-through rights does the Butterfly Fund have?**

Right of first refusal for 50% of the equity at the next fundraising post the accelerator

- **How is the Butterfly Fund investment made?**

Convertible loan (up to €150,000). The program will also help companies apply for regional non-dilutive R&D grant funding (up to €350,000).

For more information please go to www.biopark.be or send your questions to apply@biopark.be